Nuclear Medicine and Biology
Volume 35, Issue 8 , Pages 861-867 , November 2008

In vivo evaluation in rodents of [123I]-3-I-CO as a potential SPECT tracer for the serotonin 5-HT2A receptor

Received 22 May 2008 ,Revised 5 September 2008 ,Accepted 8 September 2008.

References 

  1. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38:1083–1152
  2. Audenaert K, Van Laere K, Dumont F, Slegers G, et al. Decreased frontal serotonin 5-HT2a receptor binding index in deliberate self-harm patients. Eur J Nucl Med. 2001;28:175–182
  3. Audenaert K, Van Laere K, Dumont F, Vervaet M, et al. Decreased 5-HT2a receptor binding in patients with anorexia nervosa. J Nucl Med. 2003;44:163–169
  4. Hashimoto T, Kitamura N, Kajimoto Y, Shirai Y, et al. Differential changes in serotonin 5-Ht(1A) and 5-Ht(2) receptor-binding in patients with chronic-schizophrenia. Psychopharmacology. 1993;112:S35–S39
  5. Meyer JH, Kapur S, Houle S, DaSilva J, et al. Prefrontal cortex 5-HT2 receptors in depression: an [F-18]setoperone PET imaging study. Am J Psychiatry. 1999;156:1029–1034
  6. Mintun MA, Sheline YI, Moerlein SM, Vlassenko AG, et al. Decreased hippocampal 5-HT2A receptor binding in major depressive disorder: in vivo measurement with [18F]altanserin positron emission tomography. Biol Psychiatry. 2004;55:217–224
  7. Peremans K, Audenaert K, Blanckaert P, Jacobs F, et al. Effects of aging on brain perfusion and serotonin-2A receptor binding in the normal canine brain measured with single photon emission tomography. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:1393–1404
  8. Peremans K, Audenaert K, Coopman F, Blanckaert P, et al. Estimates of regional cerebral blood flow and 5-HT2A receptor density in impulsive, aggressive dogs with Tc-99m-ECD and I-123-5-I-R91150. Eur J Nucl Med Mol Imaging. 2003;30:1538–1546
  9. Peremans K, Audenaert K, Hoybergs Y, Otte A, et al. The effect of citalopram hydrobromide on 5-HT2A receptors in the impulsive-aggressive dog, as measured with I-123-5-I-R91150 SPECT. Eur J Nucl Med Mol Imaging. 2005;32:708–716
  10. Halldin C, Lundkvist C, Ginovart N, Nyberg S, et al. [C-11]MDL 100907, a radioligand for selective imaging of 5-HT2A receptors with PET. J Nucl Med. 1996;37:424
  11. Marner L, Knudsen GM, Madsen K, Haugbol S, et al. Longitudinal assessment of cerebral 5-HT2A receptors in normal volunteers. An [18F]-altanserin PET study. Neuroimage. 2006;31:T101
  12. Ngan ETC, Yatham LN, Ruth TJ, Liddle PF. Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: a PET study using [F-18]setoperone. Am J Psychiatry. 2000;157:1016–1018
  13. Catafau AM, Danus M, Bullich S, Llop J, et al. Characterization of the SPECT 5-HT2A receptor ligand I-123-R91150 in healthy volunteers: Part 1 — pseudoequilibrium interval and quantification methods. J Nucl Med. 2006;47:919–928
  14. Catafau AM, Danus M, Bullich S, Nucci G, et al. Characterization of the SPECT 5-HT2A receptor ligand I-123-R91150 in healthy volunteers: Part 2 — ketanserin displacement. J Nucl Med. 2006;47:929–937
  15. Fu X, Tan PZ, Kula NS, Baldessarini R, et al. Synthesis, receptor potency, and selectivity of halogenated diphenylpiperidines as serotonin 5-HT2A ligands for PET or SPECT brain imaging. J Med Chem. 2002;45:2319–2324
  16. Blanckaert P, Burvenich I, Devos F, Slegers G. Synthesis and in vivo evaluation in mice of (I-123)-(4-fluorophenyl)(1-(3-iodophenethyl)piperidin-4-yl) methanone as a potential SPECT-tracer for the serotonin 5-HT2A receptor. J Label Compounds Radiopharm. 2007;50:183–188
  17. Hendrikse NH, Franssen EJ, Van der Graaf WTA, Vaalburg W, et al. Visualization of multidrug resistance in vivo. Eur J Nucl Med. 1999;26:283–293
  18. Elsinga PH, Hendrikse NH, Bart J, van Waarde A, et al. Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain. Mol Imaging Biol. 2005;7:37–44
  19. Ishiwata K, Kawamura K, Yanai K, Hendrikse NH. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J Nucl Med. 2007;48:81–87
  20. Kiyono Y, Yamashita T, Doi H, Kuge Y, et al. Is MIBG a substrate of P-glycoprotein?. Eur J Nucl Med Mol Imaging. 2007;34:448–452
  21. Marian T, Szabo G, Goda K, Nagy H, et al. In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance. Eur J Nucl Med Mol Imaging. 2003;30:1147–1154
  22. de Vries EFJ, Kortekaas R, van Waarde A, Dijkstra D, et al. Synthesis and evaluation of dopamine D-3 receptor antagonist C-11-GR218231 as PET tracer for P-glycoprotein. J Nucl Med. 2005;46:1384–1392
  23. Liow JS, Lu SY, McCarron JA, Hong JS, et al. Effect of a P-glycoprotein inhibitor, cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [C-11](R)-(−)-RWAY. Synapse. 2007;61:96–105

PII: S0969-8051(08)00183-2

doi: 10.1016/j.nucmedbio.2008.09.004

Nuclear Medicine and Biology
Volume 35, Issue 8 , Pages 861-867 , November 2008

Article Tools

* Image Usage & Resolution